Epoque, the personal financial investment company in which HLB Group Chairman Jin Yang-gon holds a 99% stake, bought additional shares of HLB Innovation and HLB Therapeutics ahead of clinical trial updates. It acquired 218,718 HLB Innovation shares for 3.574 billion Korean won between September 23 and October 1, lifting its holdings to 294,412 shares from 75,694. Epoque also bought 130,584 HLB Therapeutics shares for approximately 291 million Korean won through purchases on September 23, September 30 and October 1, increasing its holdings to 172,272 shares from 41,688. HLB Therapeutics plans to announce November top-line results from the global Phase 3 SEER-2 trial of RGN-259 for neurotrophic keratitis. Verismo Therapeutics, HLB Innovation’s U.S. subsidiary, plans to present interim Phase 1 results for its SynKIR-310 CAR-T (genetically engineered cancer therapy) treatment at the American Society of Hematology in December. Jin has also acquired approximately 1.22 million affiliate shares through 62 transactions under his personal name this year. HLB Group said the purchases reflect his confidence in its new drug projects, follow-up pipelines and affiliates’ mid- to long-term growth potential.